Difference between revisions of "Mitoxantrone (Novantrone)"
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Hodgkin lymphoma " to "[[Category:Classical Hodgkin lymphoma ") |
Warner-admin (talk | contribs) m (Text replacement - "Hodgkin lymphoma" to "Classical Hodgkin lymphoma") |
||
Line 21: | Line 21: | ||
**[[B-cell lymphoma of mucosa-associated lymphoid tissue]] | **[[B-cell lymphoma of mucosa-associated lymphoid tissue]] | ||
**[[Diffuse large B-cell lymphoma]] | **[[Diffuse large B-cell lymphoma]] | ||
− | **[[Hodgkin lymphoma]] | + | **[[Classical Hodgkin lymphoma]] |
**[[Marginal zone lymphoma]] | **[[Marginal zone lymphoma]] | ||
*[[Prostate cancer]] | *[[Prostate cancer]] |
Revision as of 19:13, 9 June 2023
General information
Class/mechanism: Synthetic antineoplastic anthracenedione, intercalates into DNA, causing crosslinking and strand breaks. Mitoxantrone inhibits topoisomerase II, which helps to uncoil and repair damaged DNA. It also has been observed to interfere with RNA and has activity against resting and proliferating cells. In vitro, it has been observed to interfere with antigen presentation; inhibit B-cell, T-cell, and macrophage proliferation; and decrease secretion of interferon gamma, tumor necrosis factor-alpha (TNF-α), and interleukin-2 (IL-2).[1][2]
Route: IV
Extravasation: irritant (usually), vesicant (rare)
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is established (work in progress)
- Non-Hodgkin lymphoma
Diseases for which it is used
- B-cell acute lymphoblastic leukemia
- Acute myeloid leukemia
- Acute promyelocytic leukemia
- Breast cancer
- Non-Hodgkin lymphoma
- Prostate cancer
- T-cell acute lymphoblastic leukemia
Diseases for which it was used
Patient drug information
- Mitoxantrone (Novantrone) patient drug information (Chemocare)[3]
- Mitoxantrone (Novantrone) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1987-12-23: Initial FDA approval for the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias. (Based on Arlin et al. 1990)
- 1996-11-13: Approved in combination with corticosteroids as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. (Based on CALGB 9182, CCI-NOV22, Moore et al. 1994)
Also known as
- Generic name: mitozantrone
- Brand names: Nitrol, Novantron, Novantrone
References
- Drugs
- Intravenous medications
- Irritant
- Anthracenedione
- Topoisomerase inhibitors
- B-cell acute lymphoblastic leukemia medications
- Acute myeloid leukemia medications
- Acute promyelocytic leukemia medications
- Breast cancer medications
- Diffuse large B-cell lymphoma medications
- Follicular lymphoma medications
- Classical Hodgkin lymphoma medications
- MALT lymphoma medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Prostate cancer medications
- T-cell acute lymphoblastic leukemia medications
- Chronic lymphocytic leukemia medications (historic)
- FDA approved in 1987